Evoke Pharma, Inc. (NASDAQ:EVOK) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Several other brokerages have also weighed in on EVOK. Ascendiant Capital Markets raised their target price on Evoke Pharma from $5.00 to $6.00 and gave the stock an “in-line” rating in a research report on Thursday, March 16th. Rodman & Renshaw reaffirmed a “buy” rating and set a $9.00 price target (up previously from $6.00) on shares of Evoke Pharma in a research report on Thursday, March 16th. HC Wainwright set a $9.00 price target on Evoke Pharma and gave the stock a “buy” rating in a research report on Thursday, March 16th. Zacks Investment Research lowered Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 20th. Finally, FBR & Co reaffirmed a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research report on Thursday, May 18th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Evoke Pharma currently has a consensus rating of “Hold” and a consensus price target of $7.25.

Evoke Pharma (EVOK) traded down 1.15% during trading on Friday, hitting $2.59. 81,109 shares of the stock traded hands. Evoke Pharma has a 12 month low of $1.35 and a 12 month high of $11.11. The company’s market cap is $39.85 million. The company’s 50 day moving average price is $2.57 and its 200 day moving average price is $2.66.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Monday, May 15th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same period last year, the business posted ($0.45) EPS. On average, equities research analysts anticipate that Evoke Pharma will post ($0.81) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Evoke Pharma, Inc. (NASDAQ:EVOK) Upgraded at ValuEngine” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/07/evoke-pharma-inc-nasdaqevok-upgraded-at-valuengine.html.

A hedge fund recently raised its stake in Evoke Pharma stock. State Treasurer State of Michigan boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 62.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 291,966 shares of the specialty pharmaceutical company’s stock after buying an additional 111,966 shares during the period. State Treasurer State of Michigan owned about 2.37% of Evoke Pharma worth $905,000 as of its most recent SEC filing. 11.76% of the stock is owned by hedge funds and other institutional investors.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.